ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ontunisertib

Also written as “Ontunisertib”, “AGMB-129” and “[14C]ontunisertib”.

Its studies are mostly in Crohn Disease, led by 2 companies.

Drug pageOntunisertib: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Apr 25, 20237 company-led studies, 2 open or runningNext primary completion: Dec 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Agomab Therapeutics NVits history only62 open or runningphase 2since Apr 25, 2023Apr 25, 2023Dec 31, 2028phase 2 · NCT07683325
Origo Biopharma10 open or runningphase 1since Jun 18, 2021Jun 18, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Origo Biopharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 18, 2021First study: phase 1 study in Healthy VolunteersFirst studyNCT04933565 · 81 enrolled · Spain
  2. Feb 13, 2025Named ontunisertibINNProposed as its International Nonproprietary Name in WHO's List 132 · before, AGMB-129, ORG-129

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Origo Biopharma leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04933565Healthy Volunteers · Spain1CompletedDec 12, 202281

How it is read

Names in the registry

  • “Ontunisertib”, 4 entries
  • “AGMB-129”, 4 entries
  • “[14C]ontunisertib”, 2 entries
  • “ORG-129”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.